Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 5Terminated 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1

Interventions

pembrolizumab 33Carboplatin 18Cisplatin 15Nivolumab 14Pemetrexed 12Paclitaxel 12atezolizumab 11Ipilimumab 11venetoclax 10Radiotherapy 10Gemcitabine 10durvalumab 9Docetaxel 9fludarabine 8Cyclophosphamide 8Specimen Handling 7Biopsy 7Bevacizumab 7tislelizumab 6fludarabine phosphate 6enzalutamide 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6tazemetostat 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Liposomes × 90 days × Clear all
NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡